Zhejiang Starry Pharm Co Ltd603520
▼ NegativeCapitalrelevance
Non-recurring net profit fell 48.5% in H1 and swung to a loss in Q2, indicating weaker underlying profitability.
Impact on stocks 1
Others
Zhejiang Starry Pharm Co LtdStar Lake released its 2026 interim report. In the first half, operating revenue was 1.41 billion yuan, up 1.2% year on year. Net profit attributable to the parent was 39.93 million yuan, up 37.1% year on year, but non-recurring net profit attributable to the parent was 14.04 million yuan, down 48.5% year on year. In the second quarter, operating revenue was 703 million yuan, down 1.2% year on year. Net profit attributable to the parent was 18.98 million yuan, up 28.3% year on year, while non-recurring net profit attributable to the parent was a loss of 2.82 million yuan, down 117.5% year on year. As of the end of the second quarter, total assets were 5.997 billion yuan, down 2.6% from the end of the previous year, and net assets attributable to the parent were 2.477 billion yuan, down 3.2%. The company said its active pharmaceutical ingredient business continued to grow, but sales of some products were constrained by production capacity. The intermediate business was adjusted flexibly, and the formulation business advanced its integration strategy. During the reporting period, the company completed the sale of equity in an associate and recognized investment income, which is expected to have a certain impact on operations but does not involve adjustments to its main business. Demand in the iodine contrast agent market is steadily rising, providing a foundation for sustainable improvement in future performance.
Zhejiang Starry Pharm Co LtdNon-recurring net profit fell 48.5% in H1 and swung to a loss in Q2, indicating weaker underlying profitability.